Form 8-K - Current report:
SEC Accession No. 0000950170-23-002531
Filing Date
2023-02-13
Accepted
2023-02-13 06:59:56
Documents
12
Period of Report
2023-02-10
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K axsm-20230210.htm   iXBRL 8-K 59158
  Complete submission text file 0000950170-23-002531.txt   172053

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT axsm-20230210_lab.xml EX-101.LAB 12806
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT axsm-20230210.xsd EX-101.SCH 2451
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT axsm-20230210_pre.xml EX-101.PRE 9441
6 EXTRACTED XBRL INSTANCE DOCUMENT axsm-20230210_htm.xml XML 4540
Mailing Address 22 CORTLANDT STREET, 16TH FLOOR NEW YORK NY 10007
Business Address 22 CORTLANDT STREET, 16TH FLOOR NEW YORK NY 10007 (212) 332-3241
Axsome Therapeutics, Inc. (Filer) CIK: 0001579428 (see all company filings)

EIN.: 454241907 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37635 | Film No.: 23614627
SIC: 2834 Pharmaceutical Preparations